San Diego, United States
ForHumanity Health, Inc., founded in 2025, is setting the stage for a revolution in precision medicine. With the guiding slogan, "Transforming proven drugs into faster, safer, human-centered therapies through telehealth and inhalable science," the company is at the forefront of ensuring proven drugs are more efficiently delivered to patients.
At the heart of ForHumanity's innovation is its proprietary microencapsulation and dry-powder inhalation technologies, which spearhead a new frontier in drug reformulation. By transitioning FDA-approved molecules into rapid-onset therapeutics, they present a compelling alternative to traditional oral medications. Their flagship products include VigorAir™ (for men’s health), ZapMigraine™ (for migraines), and MetaChew™ (for metabolic health and longevity).
Under the leadership of a distinguished team from notable institutions like Harvard and Auspex Pharmaceuticals, and companies such as CrowdStrike and Sonos, they leverage an extensive IP portfolio. Positioned to redefine the healthcare landscape, ForHumanity Health integrates prescription inhalables and telemedicine into one seamless ecosystem, prioritizing real human outcomes.
